Identifying molecular biomarkers that predict cancer drug efficacy is crucial for the advancement of precision medicine. In this issue of Cell, Iorio et al. nominate hundreds of potential genetic and epigenetic biomarkers through high-throughput drug screening in 1,000 molecularly annotated cancer cell lines.
Developing personalized therapies that exploit the unique molecular abnormalities in a patient's tumor is a central objective of modern cancer research. Genome sequencing initiatives, such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC), have defined the complex genetic landscapes of the most common human malignancies; however, only a small percentage of cancer mutations is considered to be actionable with existing therapies (Garraway and Lander, 2013; Stratton et al., 2009) . While new targets and drugs are clearly needed, a major obstacle in implementing precision therapies is our incomplete understanding of the relationship between tumor genotype and drug sensitivity. To address this issue, many investigators have turned to large-scale chemical screens in genetically annotated human cancer cell lines as a means of nominating predictive biomarkers (Figure 1 ). While cancer cell lines in culture are imperfect models of human tumors, they tend to remain addicted to the oncogenes that initiated tumor formation and hence are well-validated tools for studying oncogene-targeted therapies (Sharma et al., 2010) . In this issue, Iorio et al. present one of the largest attempts to date at mining predictive correlates of drug sensitivity using a panel of 1,000 annotated cancer cell lines treated with 265 compounds (Iorio. et al., 2016) .
The strategy taken by the authors is the following: (1) perform a deep genetic and epigenetic analysis of each cell line, focusing on the features that match the recurrent alterations found in human tumors, (2) measure the sensitivity of each cell line to 265 different compounds/ drugs, which includes approved and investigational agents, and (3) perform computational analyses to search for genetic/epigenetic alterations that correlate with resistance and sensitivity to each drug. Several important observations have been made during the implementation of this screening platform. First, the large panel of cell lines used in this study capture much of the gene mutations, DNA copy number alterations, and epigenetic changes found in primary human tumors. Furthermore, the authors use machine learning to investigate which data type (genomic alterations, DNA methylation, or gene expression) is the best predictor of drug sensitivity. When performing a pan-cancer analysis, gene expression is the superior predictor of sensitivity, whereas within a specific cancer, drug sensitivity is best explained by genomic analysis. Importantly, many of the pharmacogenomic relationships identified in Iorio et al. could be validated when evaluating prior analyses of the Cancer Cell Line Encyclopedia (CCLE) (Barretina et al., 2012; Seashore-Ludlow et al., 2015) , thus alleviating concerns about the reproducibility of results from independent drug screening platforms (Haibe-Kains et al., 2013) . Taken together, these findings provide significant insight into our assessment of human cancer cell lines and drug sensitivity profiling as tools for therapeutic investigation.
The output of the analysis in Iorio et al. is a stunning number of genotype-drug sensitivity associations. In total, 688 statistically significant interactions have been identified between individual genetic/epigenetic events and specific cancer drugs, with 262 of these associations being classified as large effect-that is, reaching a comparable strength of association as observed between clinically validated kinase inhibitors and their genetically altered kinase target (imatinib/BCR-ABL, vemurafinib/BRAF V600E ). We list here just a few of these novel associations: sensitivity to the anti-androgen bicalutamide in squamous cell lung cancer lines has been found to be associated with inactivating mutations of the chromatin modifier MLL2. In stomach cancer cell lines, truncating mutations of the transcriptional corepressor BCOR are associated with sensitivity to LY317615, an inhibitor of protein kinase C b. Sensitivity to the BRD2/BRD3/BRD4 bromodomain inhibitor JQ1 in breast cancer lines is linked to the mutational status of the RNA polymerase II subunit POLR2B. The functional relationship between these non-oncogene drug targets and these specific genetic alterations is presumably indirect and can be contrasted with the classical targeted therapy paradigm of direct oncoprotein inhibition (e.g., imatinib/BCR-ABL) (Luo et al., 2009) . Hence, this study may have exposed a vast array of synthetic-lethality genetic interactions for future mechanistic characterization (Kaelin, 2005) .
When Iorio et al. is considered together with other large-scale compound screening initiatives (Figure 1 ), it becomes apparent that an explosion of new biomarker-guided therapeutic opportunities is emerging, which now await validation in pre-clinical models and/or in cancer patients. Unfortunately, the historical experience of pharma and academia in developing drugs against non-oncogene drug targets, in particular those discovered in cell lines, would lead us to anticipate a low probability of success during clinical translation. However, the analysis presented in Iorio et al. may have addressed the critical issue that has undermined the prior pursuits of non-oncogene targets: the lack of predictive genetic biomarkers. A key question going forward will be whether the inherent limitation of cancer cell lines as tumor models will obfuscate the pharmacogenomic relationships identified in this study, as validation experiments proceed into more physiological tumor models. Despite these concerns, the remarkable scale of this cell line screening effort places us in a strong position of having hundreds of potential hypotheses to be explored. Hence, even a low rate of validation could still amount to a major advance in the development of targeted cancer therapies. In this regard, a largescale drug efficacy evaluation in genetically annotated patient-derived xenograft (PDX) tumor models would be a justified follow-up venture to this work.
While the clinical significance of the findings in Iorio et al. remains to be determined, the utility of this cell line resource for basic cancer research is unambiguous. NCI-60 was initiated in the 1980s as the first compound screening initiative in cancer lines and contributed fundamental insights to our understanding of drug mechanisms of action (Chabner, 2016) . The deepening genomic, epigenomic, and, ultimately, metabolomic characterization of cell lines is allowing investigators to pinpoint cancer-sustaining molecular mechanisms with unprecedented depth, rigor, and speed. As such efforts have expanded in recent years, it is now common practice in many research labs, including our own, to use publicly available cancer cell line resources to guide the experimental evaluation of any new gene or small molecule for its relevance to cancer biology. The NCI-60 project was initiated in the 1980s and has to date tested >100,000 compounds in 59 cancer cell lines. More recently, the scale of cancer cell line drug screens has expanded dramatically (e.g., Cancer Cell Line Encyclopedia [CCLE]/Cancer Therapeutics Response Portal [CTRP] , and Genomics of Drug Sensitivity in Cancer [GDSC] ) and now includes a detailed genetic analysis of each cell line.
